A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Mullane, Kathleen M;Winston, Drew J;Nooka, Ajay;Morris, Michele I;Stiff, Patrick;Dugan, Michael J;Holland, Henry;Gregg, Kevin;Adachi, Javier A;Pergam, Steven A;Alexander, Barbara D;Dubberke, Erik R;Broyde, Natalya;Gorbach, Sherwood L;Sears, Pamela S;
clinical infectious diseases 2019 Vol. 68 pp. 196-203
217
m2019clinicala

Abstract

Patients undergoing hematopoietic stem cell transplantation are at elevated risk for development of Clostridium difficile–associated diarrhea (CDAD). Fidaxomici

Keywords

Access

URL:
https://academic.oup.com/cid/article/68/2/196/5035...

Citation

ID: 115564
Ref Key: m2019clinicala
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
115564
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store